AU
BIO icon

AlphaGrep UK’s Bio-Rad Laboratories Class A BIO Stock Holding History

AlphaGrep UK’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$249K Buy
+847
New +$240K 0.07% 588

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

AlphaGrep UK's BIO Position: Q2 2026 in Review

AlphaGrep UK opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 847 shares worth $249K. The stake represents 0.07% of the portfolio and ranks #588 among its holdings.

370 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • AlphaGrep UK held 847 shares of Bio-Rad Laboratories Class A worth $249K as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new AlphaGrep UK position in Q2 2026.
  • Bio-Rad Laboratories Class A made up 0.07% of AlphaGrep UK's portfolio in Q2 2026, its #588 holding.
  • 370 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.